RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hikma Pharmaceuticals - Stock

Hikma Pharmaceuticals Net Income 2024

Hikma Pharmaceuticals Net Income

463.63 M USD

Ticker

HIK.L

ISIN

GB00B0LCW083

WKN

A0HG69

In 2024, Hikma Pharmaceuticals's profit amounted to 463.63 M USD, a 144.02% increase from the 190 M USD profit recorded in the previous year.

The Hikma Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2029e-
2028e629.29
2027e610.14
2026e559.74
2025e511.97
2024e463.63
2023190
2022188
2021421
2020431
2019486
2018282
2017-843
2016155
2015252
2014278
2013212
2012100.3
201180.1
201098.8
200977.7
200857.1
200762.6
200654.5
200543.9
200437.5

Hikma Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hikma Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hikma Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hikma Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hikma Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hikma Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hikma Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hikma Pharmaceuticals’s growth potential.

Hikma Pharmaceuticals Revenue, Profit, and EBIT History

DateHikma Pharmaceuticals RevenueHikma Pharmaceuticals EBITHikma Pharmaceuticals Net Income
2029e3.74 B undefined0 undefined0 undefined
2028e3.62 B undefined855.69 M undefined629.29 M undefined
2027e3.48 B undefined815.25 M undefined610.14 M undefined
2026e3.34 B undefined770.36 M undefined559.74 M undefined
2025e3.19 B undefined726.52 M undefined511.97 M undefined
2024e3.09 B undefined684.17 M undefined463.63 M undefined
20232.88 B undefined622 M undefined190 M undefined
20222.52 B undefined509 M undefined188 M undefined
20212.55 B undefined559 M undefined421 M undefined
20202.34 B undefined526 M undefined431 M undefined
20192.2 B undefined474 M undefined486 M undefined
20182.08 B undefined449 M undefined282 M undefined
20171.94 B undefined386 M undefined-843 M undefined
20161.95 B undefined419 M undefined155 M undefined
20151.44 B undefined381 M undefined252 M undefined
20141.49 B undefined402 M undefined278 M undefined
20131.37 B undefined352 M undefined212 M undefined
20121.11 B undefined166.8 M undefined100.3 M undefined
2011918 M undefined118.7 M undefined80.1 M undefined
2010730.9 M undefined127.9 M undefined98.8 M undefined
2009636.9 M undefined114.7 M undefined77.7 M undefined
2008580.7 M undefined94.3 M undefined57.1 M undefined
2007448.8 M undefined92.4 M undefined62.6 M undefined
2006317 M undefined74.3 M undefined54.5 M undefined
2005262.2 M undefined67.8 M undefined43.9 M undefined
2004214.1 M undefined61.2 M undefined37.5 M undefined

Hikma Pharmaceuticals stock margins

The Hikma Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hikma Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hikma Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hikma Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Hikma Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hikma Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hikma Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hikma Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hikma Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hikma Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hikma Pharmaceuticals Margin History

Hikma Pharmaceuticals Gross marginHikma Pharmaceuticals Profit marginHikma Pharmaceuticals EBIT marginHikma Pharmaceuticals Profit margin
2029e48.94 %0 %0 %
2028e48.94 %23.61 %17.36 %
2027e48.94 %23.46 %17.56 %
2026e48.94 %23.09 %16.77 %
2025e48.94 %22.8 %16.07 %
2024e48.94 %22.15 %15.01 %
202348.94 %21.63 %6.61 %
202250.26 %20.22 %7.47 %
202150.96 %21.9 %16.49 %
202051.82 %22.47 %18.41 %
201949.7 %21.52 %22.06 %
201851.64 %21.63 %13.58 %
201750.26 %19.94 %-43.54 %
201652.21 %21.49 %7.95 %
201556.81 %26.46 %17.5 %
201457.15 %27 %18.67 %
201355.97 %25.79 %15.53 %
201245.2 %15.04 %9.05 %
201143.06 %12.93 %8.73 %
201048.88 %17.5 %13.52 %
200947.79 %18.01 %12.2 %
200844.17 %16.24 %9.83 %
200749.35 %20.59 %13.95 %
200650 %23.44 %17.19 %
200551.79 %25.86 %16.74 %
200451.47 %28.58 %17.52 %

Hikma Pharmaceuticals Aktienanalyse

What does Hikma Pharmaceuticals do?

Hikma Pharmaceuticals PLC is a global company that focuses on the manufacturing and distribution of high-quality generics and specialty medications. The company was founded in Jordan in 1978 and is headquartered in London, UK. Over the years, Hikma Pharmaceuticals PLC has consistently grown and is now one of the leading generic manufacturers worldwide. The company operates in three core business areas: generics, injectables, and branded pharmaceuticals. It specializes in producing medications for diseases such as HIV/AIDS, cancer, and cardiovascular diseases. It also manufactures generics for anesthesia and opioid painkillers. In addition, Hikma Pharmaceuticals PLC produces injectable medications, particularly sterile injectables, used in emergency medicine, intensive care, and oncology. The company also develops proprietary medications based on specific patient needs and has its own pipeline of branded pharmaceuticals. It distributes over 1,000 medications in more than 50 countries, with production facilities in several countries including Jordan, Saudi Arabia, Portugal, Italy, and the United States. Hikma Pharmaceuticals PLC has shown strong performance in recent years, reflected in positive financial results. It prioritizes efficient production, strict quality standards, and smart investments to strengthen its market presence and innovation capability. The company has built a reputation as a reliable partner for customers and investors. In summary, Hikma Pharmaceuticals PLC is a global company engaged in the production and distribution of generics, injectables, and proprietary medications. It is known for its high-quality and cost-effective generics, broad product range, and strong international network. The company has established itself as a trusted partner for customers and investors and will continue to play a significant role in the pharmaceutical industry. Hikma Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Hikma Pharmaceuticals's Profit Margins

The profit margins of Hikma Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Hikma Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Hikma Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Hikma Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Hikma Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Hikma Pharmaceuticals Stock

How much profit has Hikma Pharmaceuticals made this year?

Hikma Pharmaceuticals has made 463.63 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 144.02% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Hikma Pharmaceuticals publish its earnings?

Hikma Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Hikma Pharmaceuticals?

The profits of Hikma Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Hikma Pharmaceuticals?

You can learn more about the earnings of Hikma Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Hikma Pharmaceuticals pay?

Over the past 12 months, Hikma Pharmaceuticals paid a dividend of 0.49 USD . This corresponds to a dividend yield of about 1.98 %. For the coming 12 months, Hikma Pharmaceuticals is expected to pay a dividend of 0.52 USD.

What is the dividend yield of Hikma Pharmaceuticals?

The current dividend yield of Hikma Pharmaceuticals is 1.98 %.

When does Hikma Pharmaceuticals pay dividends?

Hikma Pharmaceuticals pays a quarterly dividend. This is distributed in the months of September, April, September, April.

How secure is the dividend of Hikma Pharmaceuticals?

Hikma Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Hikma Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.52 USD are expected. This corresponds to a dividend yield of 2.09 %.

In which sector is Hikma Pharmaceuticals located?

Hikma Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hikma Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hikma Pharmaceuticals from 5/3/2024 amounting to 0.371 USD, you needed to have the stock in your portfolio before the ex-date on 3/21/2024.

When did Hikma Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/3/2024.

What was the dividend of Hikma Pharmaceuticals in the year 2023?

In the year 2023, Hikma Pharmaceuticals distributed 0.442 USD as dividends.

In which currency does Hikma Pharmaceuticals pay out the dividend?

The dividends of Hikma Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Hikma Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Hikma Pharmaceuticals

Our stock analysis for Hikma Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hikma Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.